VILNIUS, Lithuania and TAIPEI, Taiwan, April 30, 2018 /PRNewswire/ -- TheVax Genetics VaccineCO., Ltd (6567.TWO) and Biotechpharma UAB have entered into a manufacturing agreement to produce THEVAX HBV vaccine for first-in-human clinical trials.
"The THEVAX HBV vaccine has been developed employing our
"We are delighted to be working with TheVax Genetics Vaccine CO on this exciting project and with great enthusiasm look forward to seeing it enter clinical trials," comments Vladas Bumelis, CEO of Biotechpharma. "Biotechpharma is well positioned to facilitate successful process transfer and manufacture of HBV vaccine in rapid time-frames, with focus on high quality and excellence in service."
About TheVax Genetics Vaccine CO., Ltd
TheVax Genetics Vaccine CO. Ltd is a publicly traded Taiwan-based company engaged in development of human vaccines. The Company's main products include therapeutic monovalent vaccines TVGV-1 and multivalent vaccines TVGV-2 for treatment of cervical cancer and precancerous lesions, and therapeutic vaccines TVGV-HBV for treatment of Hepatitis B.
About Biotechpharma UAB
Biotechpharma UAB is a leading biopharmaceutical CDMO providing fully integrated process development and GMP manufacturing services globally. Biotechpharma has extensive experience in the production of new biological entities, having 150 employees at its state-of-the-art facility in Vilnius, Lithuania.
View original content:http://www.prnewswire.com/news-releases/thevax-genetics-vaccine-co-ltd-and-biotechpharma-uab-to-collaborate-on-cgmp-production-of-thevax-hbv-vaccine-300638279.html
SOURCE Biotechpharma UAB
Subscribe to our Free Newsletters!